Cancer Biomarker Market Report 2026

Cancer Biomarker Market Overview

• Cancer Biomarker market size has reached to $25.09 billion in 2025 • Expected to grow to $52.63 billion in 2030 at a compound annual growth rate (CAGR) of 16% • Growth Driver: The Surging Incidence Of Cancer Fueling Growth In The Cancer Biomarker Market • Market Trend: Advancements In AI-Powered Cancer Biomarkers: Enhancing Diagnosis And Treatment Precision • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Biomarker Market?

A cancer biomarker refers to a biological molecule present in the blood, tissues, or other bodily fluids, that indicates the presence of normal or abnormal activity, as well as a condition or disease. Cancer biomarkers are used to characterize alterations in the tumor. The main types of cancer biomarker are protein biomarkers, genetic biomarkers, and other that uses omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics profiling technologies. Protein biomarkers refer to detectable flags in a patient's blood that corresponds with significant events or signal distinct states in a biological process, such as disease progression. Protein biomarkers are used to perform accurate disease diagnosis. The cancer biomarker is used in various cancer such as breast cancer, lung cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, and other cancers. It is used in diagnostics, research and development, prognostics, risk assessment, and other applications.

What Is The Cancer Biomarker Market Growth Forecast?

The cancer biomarker market size is expected to see rapid growth in the next few years. It will grow to $52.63 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising investments in precision medicine, expansion of biomarker-driven drug development, growing use of ai-based biomarker analysis, increasing focus on early-stage cancer screening. Major trends in the forecast period include increasing use of genetic and protein biomarkers, rising adoption of companion diagnostics, growing integration of omics technologies, expansion of liquid biopsy applications, enhanced focus on early cancer detection.

Global Cancer Biomarker Market Segmentation

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types 2) By Profiling Technologies: Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics 3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers 4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications Subsegments: 1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein 2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles 3) By Other Biomarker Types: Epigenetic Biomarkers, Metabolomic Biomarkers

What Is The Driver Of The Cancer Biomarker Market?

The rising incidence of cancer is driving the growth of the cancer biomarker market. The cancer incidence rate is the number of new cancers of a specific site/type that occur in a given population during a given year, represented as cancers per 100,000 people at risk. The increasing incidence of cancer is leading to the widespread use of cancer biomarkers because it helps in assessing disease risk, screening for occult primary tumors, identifying benign from malignant signs, or separating one form of malignancy from another. Cancer biomarkers help in the early detection, diagnosis, and monitoring of cancer by indicating the presence or progression of the disease, enabling personalized treatment and improving patient outcomes. For instance, in May 2024, according to a report published by the International Agency for Research on Cancer (IARC), a France-based cancer research organization, in 2022, approximately 20 million new cancer cases were reported, resulting in 9.7 million deaths, by 2050, over 35 million new cancer cases are projected, representing a 77% increase compared to 2022. Therefore, the rising incidence of cancer packaging is expected to propel the growth of the cancer biomarker industry in the coming years.

Key Players In The Global Cancer Biomarker Market

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Global Cancer Biomarker Market Trends and Insights

Major companies operating in the cancer biomarker market are focusing on developing innovative solutions, such as AI-powered cancer biomarkers, to enhance diagnostic accuracy and personalize treatment plans for patients. AI-powered cancer biomarkers refer to biological indicators of cancer that are identified and analyzed using artificial intelligence technologies. For instance, in September 2023, Ibex Medical Analytics, a US-based Ibex Medical Analytics, launched Galen Breast HER2, an AI-powered solution designed to enhance the accuracy and reproducibility of HER2 scoring in breast cancer patients. This innovative platform aids pathologists by automatically detecting invasive tumor areas and quantifying HER2 expression based on the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system utilizes a novel computational pipeline to analyze immunohistochemistry (IHC)-stained slides, providing detailed visualizations of staining patterns and enabling pathologists to make informed treatment decisions.

What Are Latest Mergers And Acquisitions In The Cancer Biomarker Market?

In June 2025, Illumina Inc., a U.S.-based genomics/sequencing technology company, acquired SomaLogic Inc. for US$ 350 million (plus up to US$ 75 million in performance‑based milestones). With this acquisition, Illumina aims to accelerate its multi‑omics strategy by integrating high-throughput proteomics (biomarker) capabilities into its sequencing platform. SomaLogicInc. a US-based clinical diagnostics company, specializes in proteomics and has developed a powerful protein-biomarker discovery platform (SomaScan) for research and disease‑profiling.

Regional Outlook

North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cancer Biomarker Market?

The cancer biomarker market consists of sales of epigenetic biomarkers, and metabolic biomarkers for various cancers such as melanoma, leukemia, bladder cancer, non-hodgkin's lymphoma, endometrial cancer, pancreatic cancer, and liver cancer. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.